BSX stock may extend its solid performance as options activity and historical patterns suggest a bullish setup with favorable ...

Boston Scientific (NYSE:BSX) recently achieved FDA approval to expand the FARAPULSE™ Pulsed Field Ablation (PFA) System's use, enhancing treatment options for persistent atrial fibrillation. This ...

Boston Scientific stock has gained 57% in 2024 but the average analyst price target sits at 101.06, according to FactSet. That represents a further 11% upside for BSX as it looks to forge a new ...

When assessing Boston Scientific’s valuation against the S&P 500, the stock presents as notably expensive across key metrics. The company’s price-to-sales (P/S) ratio stands at 8.3 ...

Boston Scientific reported revenues of $4.66 billion in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $0.75 for the same period compares with $0.56 a year ago.

Boston Scientific’s revenue climbed 32%, rising from $12.7 billion in 2022 to $16.7 billion in 2024, driven by an increase in total procedures and the introduction of new products such as POLARx ...